The Danish company It has lost market share since they started to emerge, especially in the US, similar products for the treatment of diabetes and weight loss.
The new pharmacist Nordisk will say goodbye more than 9 A thousand employees around the world. The Danish company is knowna mainly by manufacture of . With the emergence of new compounds of the same genre, the new Nordisk You are now losing market share.
As actions of the Danish pharmacist have already devalued since the beginning of the year and, to avoid even greater losses, the Administration decided to cut in jobs.
New Nordiskwhich produces the Ozempicoriginally to treat diabetes, and the Wegovyto combat obesity and lose weight, will dismiss 11% of all employees.
“Let’s simplify the structures, eliminate duplications and sharpen our focus. I know they are difficult decisions,” Mike admitted DoustdarYes .
“The changes will provide a savings of about 8 billion Danish crowns, whichQuivale At US $ 1.3 billion a year, ”he said.
A company has lost market share since similar products have started to emergeespecially those that are manufactured in the United States.
Only at the end of last year, the sales of Ozempic e Wegovy surrendered to the new Nordisk More than 42 billion euros.
